LIFE

Ethos Technologies Inc. Class A Common Stock (LIFE) | Rumor.io

Ethos Technologies

LIFE

Attention (50-day avg)0%

Attention rank (50-day avg)#3,802

Bullish sentiment (50-day avg)88%

Price to earnings ratio22.5

Market capitalization3.3B

Earnings per share-1.67

Dividend yield (TTM)—

Revenue (annual)387.6M

Net income (annual)71.2M

Social

What share of all stock conversation is about LIFE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% -0.01

Aug 3

aTyr Pharma, Inc. (LIFE) has a buyback of 100 million shares, which could positively impact the stock price.
The company's Q2 earnings report showed a 113.35% increase in revenue to $189.56M, and it expects a total revenue of $160-164M in Q3 and $727-731M for the full fiscal year 2026.
Analysts are positive about the company's share price, expecting upward pressure due to reported growth and higher outlook, but missing consensus and margin data limit the likely repricing magnitude.

Generated by AI

Sentiment

Of the messages about LIFE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.28% +64.3
Bearish	—	—	—	10.72% -64.3

Bullish· Sep 17

$LIFE has a strong potential for a breakout to $11.50, with key points at $10.80 and $12.30.
The stock's unique drug has the potential to transform the treatment of inflammatory pulmonary diseases, making it undervalued considering its potential.
$LIFE has shown signs of strength, with a possible top mover next week, and a strong daily and hourly chart with decent volume.

Bearish· Sep 14

$LIFE is expected to drop 25% from its highs according to a detailed guide on A-T-M offerings.
The stock has been subject to significant selling pressure, including a large sell-off at the top of the range.
Investors who shorted $LIFE at $8s were left with significant losses, and the stock has failed to break through key levels, causing some to question their short positions.

Generated by AI

Topics

Of the messages about LIFE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	5.85%
Analysts	—	—	—	46.7%
Controversies	—	—	—	0%
Earnings	—	—	—	0.07%
Macro	—	—	—	46.56%
Technical Analysis	—	—	—	0.83%

Analysts· Sep 14

Roth Capital maintains a "buy" rating for aTyr Pharma (LIFE) with a price target of $21.
Oppenheimer maintains an "outperform" rating for aTyr Pharma (LIFE) with a price target of $20.
Oppenheimer analyst Hartaj Singh raised the price target for aTyr Pharma (LIFE) to $20 from $14 and maintains an "outperform" rating.

Announcements· Sep 16

aTyr Pharma, Inc. (LIFE) has priced a $75 million public offering of common stock at $8 per share.
The company will issue 9,375,000 common shares as part of the offering, with expected gross proceeds of approximately $75 million.
aTyr Pharma shares have increased by 16% after the announcement, with the stock trading higher following the pricing of the underwritten public offering.

Technical Analysis· Sep 14

$LIFE has broken out over $11.80, with a key resistance level at $12.00.
The stock's price movement has been influenced by a strong upside wall, with traders holding long positions and targeting $13.
Technical indicators, including the MACD, suggest that $LIFE is nearing a potential buy signal, with a key support level at $11.30.

Generated by AI

Community

Of the messages about LIFE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	32.98%
Newcomers	—	100%	100%	67.02%

Regulars· Feb 9

The regulars are focused on the Phase 3 readout of aTyr Pharma's (LIFE) treatment, with some expressing skepticism about its potential success due to imbalances in the study's data.
The company's upcoming public offering of 22.2M shares priced at $2.25/share is being closely watched, with some participants expecting a significant impact on the stock's price.
The regulars are awaiting the completion of the public offering on February 13th, after which they may re-enter long positions in the stock, which has already seen significant price drops in pre-market trading.

Newcomers· Mar 12

Newcomers are buying $LIFE due to the popularity of the company's narrative, with one user reporting a 3.5 million baht profit after buying in on fomo.
The listing of $LIFE on WEEX is expected to be a significant event, with the exchange announcing a spot listing on March 12, 2026.
A user is speculating that $LIFE could be the last opportunity to buy the asset cheaply, citing a potential bottom and a predicted price increase.

Generated by AI

News

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - aTyr Pharma (NASDAQ:ATYR)

aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis, beginning in Q4 2026.

5d agoBenzinga

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

aTyr Pharma Inc. (NASDAQ:ATYR) secured a formal agreement with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod. Following this regulatory alignment, the company prepares to initiate study-related activities across the U.S. and Europe in the fourth quarter of 2026. Phase 3 Trial Design And Endpoints The upcoming Phase 3 clinical trial aims to assess both the overall safety and effectiveness of efzofitimod in individu

5d agoYahoo Finance

aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis

aTyr Pharma plans to begin study-related activities in the fourth quarter of 2026 after reaching FDA alignment on a global Phase 3 efzofitimod trial, although further development will require additional capital. Key Investor TakeawaysaTyr Pharma (NASDAQ:ATYR) has reached alignment with the FDA on the protocol for a Phase 3 efzofitimod study in pulmonary sarcoidosis.

5d agofinance.yahoo.com

Also Discussed

Investors talking about LIFE also mention

#	Name	Attention
1	Adaptimmune Therapeutics plc ADRADAP	0%0
2	Taoping Inc.TAOP	0%0
3	WIZ - Alpha Architect Merlyn.AI Bull-Rider Bear-Fighter ETF	——
4	Xenetic Biosciences, Inc.XBIO	0%new
5	Cohen & Steers Inc.CNS	0%0
6	Nemaura Medical Inc.NMRD	0%new
7	Virtus Diversified Income & Convertible FundACV	0%0
8	CFRX - ContraFect Corporation	——
9	Kingsway Financial Services Inc.KFS	0%new
10	J-Long Group Limited Class A Ordinary SharesJL	0%new

Ethos Technologies Inc. Class A Common Stock

Financial Services
Insurance Brokers

Ethos Technologies Inc. Class A Common Stock represents the public shares of Ethos Technologies Inc., a technology-driven insurance company focused on life insurance and related protection services. Ethos Technologies offers a digital platform that connects consumers, agents, and insurance carriers, streamlining policy discovery, underwriting, and administration through an online process. Its current offerings include term life insurance, whole life insurance, indexed universal life insurance, wills and estate planning, and supplemental health insurance products. The company also provides third-party administrator services for insurance policies in the United States, supporting the operational side of policy management and servicing. Ethos Technologies serves as a modern distribution and administration platform within the insurance market, combining software, data, and insurance products to simplify access to coverage for individuals and families.

Website

Location

90 New Montgomery Street

San Francisco, CA, 94105

United States

Social

What share of all stock conversation is about LIFE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% -0.01

Aug 3

aTyr Pharma, Inc. (LIFE) has a buyback of 100 million shares, which could positively impact the stock price.
The company's Q2 earnings report showed a 113.35% increase in revenue to $189.56M, and it expects a total revenue of $160-164M in Q3 and $727-731M for the full fiscal year 2026.
Analysts are positive about the company's share price, expecting upward pressure due to reported growth and higher outlook, but missing consensus and margin data limit the likely repricing magnitude.

Generated by AI

Sentiment

Of the messages about LIFE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.28% +64.3
Bearish	—	—	—	10.72% -64.3

Bullish· Sep 17

$LIFE has a strong potential for a breakout to $11.50, with key points at $10.80 and $12.30.
The stock's unique drug has the potential to transform the treatment of inflammatory pulmonary diseases, making it undervalued considering its potential.
$LIFE has shown signs of strength, with a possible top mover next week, and a strong daily and hourly chart with decent volume.

Bearish· Sep 14

$LIFE is expected to drop 25% from its highs according to a detailed guide on A-T-M offerings.
The stock has been subject to significant selling pressure, including a large sell-off at the top of the range.
Investors who shorted $LIFE at $8s were left with significant losses, and the stock has failed to break through key levels, causing some to question their short positions.

Generated by AI

Topics

Of the messages about LIFE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	5.85%
Analysts	—	—	—	46.7%
Controversies	—	—	—	0%
Earnings	—	—	—	0.07%
Macro	—	—	—	46.56%
Technical Analysis	—	—	—	0.83%

Analysts· Sep 14

Roth Capital maintains a "buy" rating for aTyr Pharma (LIFE) with a price target of $21.
Oppenheimer maintains an "outperform" rating for aTyr Pharma (LIFE) with a price target of $20.
Oppenheimer analyst Hartaj Singh raised the price target for aTyr Pharma (LIFE) to $20 from $14 and maintains an "outperform" rating.

Announcements· Sep 16

aTyr Pharma, Inc. (LIFE) has priced a $75 million public offering of common stock at $8 per share.
The company will issue 9,375,000 common shares as part of the offering, with expected gross proceeds of approximately $75 million.
aTyr Pharma shares have increased by 16% after the announcement, with the stock trading higher following the pricing of the underwritten public offering.

Technical Analysis· Sep 14

$LIFE has broken out over $11.80, with a key resistance level at $12.00.
The stock's price movement has been influenced by a strong upside wall, with traders holding long positions and targeting $13.
Technical indicators, including the MACD, suggest that $LIFE is nearing a potential buy signal, with a key support level at $11.30.

Generated by AI

Community

Of the messages about LIFE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	32.98%
Newcomers	—	100%	100%	67.02%

Regulars· Feb 9

The regulars are focused on the Phase 3 readout of aTyr Pharma's (LIFE) treatment, with some expressing skepticism about its potential success due to imbalances in the study's data.
The company's upcoming public offering of 22.2M shares priced at $2.25/share is being closely watched, with some participants expecting a significant impact on the stock's price.
The regulars are awaiting the completion of the public offering on February 13th, after which they may re-enter long positions in the stock, which has already seen significant price drops in pre-market trading.

Newcomers· Mar 12

Newcomers are buying $LIFE due to the popularity of the company's narrative, with one user reporting a 3.5 million baht profit after buying in on fomo.
The listing of $LIFE on WEEX is expected to be a significant event, with the exchange announcing a spot listing on March 12, 2026.
A user is speculating that $LIFE could be the last opportunity to buy the asset cheaply, citing a potential bottom and a predicted price increase.

Generated by AI

Ethos Technologies

Social

Aug 3

Bullish· Sep 17

Bearish· Sep 14

Analysts· Sep 14

Announcements· Sep 16

Technical Analysis· Sep 14

Regulars· Feb 9

Newcomers· Mar 12

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - aTyr Pharma (NASDAQ:ATYR)

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis

Why is aTyr Pharma stock surging today?

Why is aTyr Pharma stock rallying today?

aTyr Pharma reaches FDA alignment on phase 3 sarcoidosis trial

Also Discussed

Ethos Technologies Inc. Class A Common Stock

Company Information

Location

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - aTyr Pharma (NASDAQ:ATYR)

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis

Why is aTyr Pharma stock surging today?

Why is aTyr Pharma stock rallying today?

aTyr Pharma reaches FDA alignment on phase 3 sarcoidosis trial

Also Discussed

Social

Aug 3

Bullish· Sep 17

Bearish· Sep 14

Analysts· Sep 14

Announcements· Sep 16

Technical Analysis· Sep 14

Regulars· Feb 9

Newcomers· Mar 12